Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05608200 | Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC | recruiting | Phase 3 | 427 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05876832 | A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) | not yet recruiting | Phase 3 | 312 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 0 | May 26, 2023 |
| clinicaltrials |
| NCT05877872 | Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 424 | Sun Yat-sen UniversityOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05797467 | Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients | recruiting | Phase 3 | 366 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT03306121 | TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 322 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05496166 | The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 348 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05861505 | COLLISION RELAPSE Trial | recruiting | Phase 3 | 360 | Amsterdam UMC, location VUmcOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05862337 | Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. | recruiting | Phase 3 | 480 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 17, 2023 | clinicaltrials |
| NCT05860868 | Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 474 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT05854849 | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC | recruiting | Phase 3 | 244 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT04019548 | Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy(SwallPEG) | recruiting | Phase 3 | 110 | Jules Bordet InstituteOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05851014 | A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | recruiting | Phase 3 | 350 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT03948035 | Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | active not recruiting | Phase 3 | 576 | Wuerzburg University HospitalOTHER | 2 | May 6, 2023 | clinicaltrials |
| NCT04087421 | Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome | recruiting | Phase 3 | 114 | University of AarhusOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05527470 | Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 440 | Wei JiangOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05841381 | Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | not yet recruiting | Phase 3 | 876 | Fudan UniversityOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT02448992 | Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 90 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT02429687 | TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors(MOGCT-01) | recruiting | Phase 3 | 129 | Beihua KongOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02429700 | TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors(SCST-01) | recruiting | Phase 3 | 132 | Beihua KongOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05212454 | Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks | recruiting | Phase 3 | 400 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT00268476 | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy(STAMPEDE) | active not recruiting | Phase 2 / Phase 3 | 11,992 | Medical Research CouncilOTHER_GOV | 2 | Apr 18, 2023 | clinicaltrials |
| NCT03458221 | Signal TrAnsduction Pathway Activity Analysis in OVarian cancER(STAPOVER) | recruiting | Phase 2 / Phase 3 | 148 | Gynaecologisch Oncologisch Centrum ZuidOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05019846 | SRT Versus SRT+ADT in Prostate Cancer(SPA) | recruiting | Phase 3 | 310 | Marco Lorenzo BonuOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05815082 | ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer | recruiting | Phase 3 | 490 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05813015 | Study of Comparing of With and Without Sequential Therapy of S-1 | recruiting | Phase 3 | 70 | Zhejiang UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05810623 | Single-Dose Intravesical Chemotherapy After Diagnostic URS(MINERVA) | not yet recruiting | Phase 3 | 394 | David D'AndreaOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05100641 | AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM | not yet recruiting | Phase 3 | 672 | Aivita Biomedical, Inc.INDUSTRY | 0 | Apr 10, 2023 | clinicaltrials |
| NCT05804916 | Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer | recruiting | Phase 2 / Phase 3 | 556 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05805098 | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML(VHA) | recruiting | Phase 2 / Phase 3 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05767892 | YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | not yet recruiting | Phase 3 | 350 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05797077 | Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA | recruiting | Phase 3 | 346 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05255471 | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.(MITO 35B) | recruiting | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05780294 | A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC | not yet recruiting | Phase 3 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05772208 | Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy | recruiting | Phase 3 | 459 | Fudan UniversityOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT04803539 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC(Artemis) | recruiting | Phase 2 / Phase 3 | 260 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT00430183 | Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer | active not recruiting | Phase 3 | 788 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 9, 2023 | clinicaltrials |
| NCT05717764 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment | not yet recruiting | Phase 3 | 500 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 0 | Feb 8, 2023 | clinicaltrials |
| NCT05718232 | SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)(SEARCH) | not yet recruiting | Phase 3 | 136 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05698186 | Thero2-01S22 in HER2-positive Breast Cancer | not yet recruiting | Phase 3 | 320 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05699746 | CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD | not yet recruiting | Phase 3 | 38 | Zhejiang UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05674305 | Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy | recruiting | Phase 3 | 366 | Fudan UniversityOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05236972 | PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer | recruiting | Phase 3 | 323 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2022 | clinicaltrials |
| NCT02544308 | Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma(IDRIS) | active not recruiting | Phase 3 | 36 | University College, LondonOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05476432 | HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study | recruiting | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05300945 | HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 200 | Zhixin CaoOTHER | 0 | Dec 6, 2022 | clinicaltrials |
| NCT05524389 | Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions | not yet recruiting | Phase 3 | 624 | Peking Union Medical College HospitalOTHER | 0 | Nov 23, 2022 | clinicaltrials |
| NCT03150576 | Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer(PARTNER) | recruiting | Phase 2 / Phase 3 | 780 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05610332 | Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes | not yet recruiting | Phase 3 | 216 | Fujian Medical UniversityOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT05608213 | Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC | recruiting | Phase 3 | 187 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02261415 | The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial(HeLiX) | active not recruiting | Phase 3 | 1,386 | Sunnybrook Health Sciences CentreOTHER | 2 | Oct 26, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 31, 2023source: clinicaltrials